Effect of valsartan on N-terminal pro-brain natriuretic peptide in patient with stable chronic heart failure: Comparison with enalapril

Korean Circulation Journal

Volumn 41, Issue 2, 2011, Pages 61-67

  Lee, Young Soo ^a   Kim, Kee Sik ^a   Lee, Jin Bae ^a   Ryu, Jae Kean ^a   Choi, Ji Yong ^a   Kim, Byong Kyu ^a   Chang, Sung Gug ^a   Hur, Seung Ho ^b   Lee, Bong Ryeol ^c   Jung, Byung Chun ^c   Hong, Geu Ru ^d   Kim, Byung Soo ^e   Park, Tae Ho ^f   Kim, Young Dae ^f   Kim, Tae Ik ^g   Kim, Dong Soo ^h  

^a Catholic University of Daegu   (South Korea)

^b Keimyung University   (South Korea)

^c Fatima Hospital   (South Korea)

^d Yeungnam University College of Medicine   (South Korea)

^e Daedong Hospital   (South Korea)

^f Dong A University College of Medicine   (South Korea)

^g Maryknoll Hospital   (South Korea)

^h Inje University College of Medicine   (South Korea)

Author keywords

Angiotensin receptor blocker; Angiotensin Converting enzyme inhibitors; Brain natriuretic peptide; Congestive heart failure

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; VALSARTAN;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CONTROLLED STUDY; COUGHING; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 79955055478     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2011.41.2.61     Document Type: Article

References (25)

1. Harrap SB, Dominiczak AF, Fraser R, et al. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation 1996;93:1148-54. (Pubitemid 26087018)
2. Kasama S, Toyama T, Kumakura H, et al. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med 2002;43:1279-85.
3. Curtiss C, Cohn JN, Vrobel T, Franciosa JA. Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation 1978;58:763-70. (Pubitemid 9042756)
4. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north Scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987;316:1429-35.
5. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
6. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75. (Pubitemid 33126822)
7. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, vonScheidt W Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001;38:1934-41. (Pubitemid 33116567)
8. S) Kim SH, Kim JS, Baek KK, et al. Role of NT-proBNP in evaluation of functional status in congestive heart failure. Korean Circ J 2004;34:894-9.
9. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of NT-pro-natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203. (Pubitemid 24203680)
10. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration inpatients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509-16. (Pubitemid 27329427)
11. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63. (Pubitemid 41821197)
12. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13. (Pubitemid 28020159)
13. Tsutamoto T, Wada A, Maeda K, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Eur Heart J 1999;20:1799-807.
14. Chung IH, Yoo BS, Ryu HY, et al. The relationship between the early follow-up BNP level and congestive status or prognosis in acute heart failure. Korean Circ J 2006;36:200-7.
15. Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1587-93.
16. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
17. Nagaya N, Nishikimi T, Goto Y, et al. Plasma brain natriuretic peptide is a biochemical marker for the prediction ofprogressive ventricular remodeling after acute myocardial infarction. Am Heart J 1998;135:21-8. (Pubitemid 28073054)
18. Latini R, Masson S, Anand I, et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002;106:2454-8. (Pubitemid 35278801)
19. Kasama S, Toyama T, Hatori T, et al. Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure. Heart 2006;92:625-30.
20. Kohno M, Horio T, Yokokawa K, et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992;92:29-34.
21. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8. (Pubitemid 28366422)
22. Tseng DS, Kwong J, Rezvani F, Coates AO. Angiotensin-Converting enzyme-related cough among Chinese-Americans. Am J Med 2010;123:183. e11-5.
23. Woo KS, Norris RM, Nicholls G. Racial differences in incidence of cough with angiotensin-converting enzyme inhibitors (a tale of two cities). Am J Cardiol 1995;75:967-8.
24. Nishizawa A. Angiotensin-converting enzyme inhibitor induced cough among Asians. Proc UCLA Health 2000;4:35-8.
25. Yeo WW, Ramsay LE. Persistent dry cough with enalapril: incidence depends on the method used. J Hum Hypertens 1990;4:517-20. (Pubitemid 20375045)